 |
| Role of CSIR-IICT in the Synthesis of Agonist molecule for use in COVAXIN developed by Bharat Biotech International Ltd. |
New Delhi (Lisbon Times):- The unforeseen
COVID-19 pandemic has brought along several challenges to the healthcare sector
and many CSIR constituent laboratories have been working relentlessly in
partnership with industry to launch repurposed drugs through the process
development and conducting clinical trials. CSIR labs have also extensively
contributed towards the launching of diagnostic kits including Feluda and Dry
Swab Direct RT-PCR method for the screening of SARS-CoV-2.
In our country, Bharat
Biotech International Ltd. (BBIL) has emerged as the frontrunner in the
development of an indigenous vaccine for COVID-19, COVAXIN™. The vaccine
developed by BBIL is a highly purified, whole virion, inactivated SARS-CoV2.
The vaccine is formulated with Algal-IMDG, which contains chemisorbed TLR7/8
agonist onto aluminum hydroxide gel to generate the requisite type of immune
responses. Owing to the significant role played by TLR7/8 agonist molecule in
the performance of a vaccine, CSIR constituent lab, Indian Institute of
Chemical Technology (IICT) based in Hyderabad, was approached by BBIL to
develop the synthetic route for the agonist molecule with indigenous chemicals
at an affordable price and with the highest purity. This agonist molecule has aided
BBIL to scale up the production of the adjuvant.
 |
| 18 Ways to Earn Money Online from Home Without Investment |
The project was
spearheaded by Dr. Chandrasekhar, Director, and Dr. Raji Reddy, Senior A scientist from IICT and has been completed in4 months, a record time in
itself. Also, the CSIR-IICT team lead by Dr. Mohana Krishna Mudiam, Senior
Principal Scientist and Professor (AcCSIR) played a key role in the development
of an analytical method for testing TLR7/8 agonist molecule and its method
validation procedures through NABL accredited lab.
Acknowledging the work undertaken by CSIR-IICT towards the development of the novel agonist, Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “The process technology developed by CSIR-IICT for the agonist molecule is playing an important role in the production of adjuvant for COVAXIN™.”Dr. Shekhar Mande, DG, CSIR, and Secretary, DSIR complimented the CSIR-IICT team for rising to the occasion in making the process affordable and enabling the development of agonist a molecule in record time and mentioned that this is yet another instance of CSIRs commitment towards ‘Aatmanirbhar Bharat
0 Comments